ArticleClinical case reports2026
Recurrent Idiopathic Intracranial Hypertension in a Patient With Systemic Lupus Erythematosus: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic intracranial hypertension (IIH) is a rare but significant complication in patients with systemic lupus erythematosus (SLE). Its diagnosis and management can be challenging, particularly in cases of recurrence. We report the case of a 26-year-old Persian female with a history of SLE and hypertension who presented with persistent headaches and bilateral papilledema. Diagnostic workup, including lumbar puncture, revealed elevated cerebrospinal fluid (CSF) pressure consistent with IIH, without evidence of infection or other secondary causes. Initial treatment with acetazolamide led to symptom resolution and normalization of CSF pressure. However, following the discontinuation of acetazolamide after a year of symptom-free follow-up, she experienced a recurrence of IIH. High-dose acetazolamide was readministered, resulting in remission. The patient was managed with continued follow-up and a multidisciplinary approach, including adjustments to her SLE and hypertension treatments. This case underscores the importance of long-term monitoring in patients with SLE who develop IIH. It highlights the potential for IIH recurrence after treatment withdrawal, emphasizing the need for individualized management strategies and a multidisciplinary approach to ensure optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.